---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-22-000121"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2022-12-15T23:59:59+00:00"
generated_at: "2026-06-21T04:31:47.281228+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Exelixis announces CSO transition; Peter Lamb steps down; Dana Aftab promoted

## Summary
- Peter Lamb transitions from CSO to EVP, Scientific Strategy effective December 15, 2022.
- Dana T. Aftab, Ph.D., appointed as new CSO and EVP, Discovery and Translational Research.
- Dr. Aftab has over 24 years at Exelixis, most recently EVP, Business Operations.
- He previously led discovery and development of cabozantinib and streamlined translational processes.

## SEC filing metadata
- accession: 0000939767-22-000121
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2022-12-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976722000121/0000939767-22-000121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976722000121/exel-20221215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-22-000121
- JSON: https://secwatch.observer/filing/0000939767-22-000121.json
- Plain text: https://secwatch.observer/filing/0000939767-22-000121.txt

## Key facts
- Executive change
  Peter Lamb changed role as Executive Vice President, Scientific Strategy at EXELIXIS, INC..
  - Action: transitioned
  - Role: Executive Vice President, Scientific Strategy
  source text: Peter Lamb, Ph.D., currently, Executive Vice President, Scientific Strategy and Chief Scientific Officer of Exelixis, Inc. (“Exelixis” or the “Company”), will transition into a new role as Executive Vice President, Scientific Strategy, effective as of today.
  evidence_url: https://www.sec.gov/Archives/edgar/data/939767/000093976722000121/0000939767-22-000121-index.htm
- Executive change
  Dana T. Aftab was appointed as Chief Scientific Officer at EXELIXIS, INC..
  - Action: appointed
  - Role: Chief Scientific Officer
  source text: Dana T. Aftab, Ph.D., will become the Company’s next Chief Scientific Officer and will also serve as Executive Vice President, Discovery and Translational Research.
  evidence_url: https://www.sec.gov/Archives/edgar/data/939767/000093976722000121/0000939767-22-000121-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.